BriaCell Therapeutics (BCT) Q2 2025 earnings summary

Executive summary

• Advanced pivotal Phase 3 trial of Bria-IMT™ in metastatic breast cancer, with FDA Fast Track designation and positive interim survival data; initiated Phase 1/2 study of Bria-OTS™ personalized immunotherapy and expanded access policy for Bria-IMT™.

• Reported positive clinical outcomes, including median overall survival of 15.6 months in Phase 2 and 100% resolution of brain metastasis in a heavily pre-treated patient.

• Closed multiple equity offerings totaling over $17 million to fund operations and clinical development.

Financial highlights

• For the quarter ended January 31, 2025, net loss was $6.3 million, down from $11.3 million year-over-year; for the six months, net loss was $12.1 million, up from $5.3 million due to a smaller gain on warrant liability.

• Operating expenses for the quarter were $7.2 million, down from $9.8 million year-over-year, driven by lower R&D and clinical trial costs.

• Cash and cash equivalents increased to $5.0 million as of January 31, 2025, from $0.9 million at July 31, 2024, due to financing activities.

• Working capital improved to $1.9 million from a negative $3.8 million at July 31, 2024.

Outlook and guidance

• Focus remains on advancing the pivotal Phase 3 Bria-IMT™ trial and the Phase 1/2 Bria-OTS™ study.

• Management continues to seek additional capital to fund ongoing operations and clinical programs.